BACKGROUND: Glucocorticoids inhibit allergen-induced airway eosinophilia and airway hyperresponsiveness (AHR). Whether glucocorticoids mediate their effects on AHR by inhibiting eotaxin and IL-5, 2 of the principal mediators of eosinophilia, or through IL-13, an important mediator of AHR, has not been established. OBJECTIVE: We sought to investigate the effects of glucocorticoids on airway eosinophilia and the expression of IL-5, eotaxin, and IL-13 in relation to the induction of AHR in a murine model of allergic asthma. METHODS: Dexamethasone (4 mg/kg) and mAbs against eotaxin (80 micro g/kg) and IL-5 (100 micro g/kg) singly and in combination were administered to immunized mice before antigen challenge. Airway responsiveness to methacholine was measured in anesthetized and mechanically ventilated animals. Eotaxin, IL-5, and IL-13 in bronchoalveolar lavage fluid (BALF), lung homogenates, or both were measured by means of ELISA. RESULTS: A single antigen challenge induced AHR that lasted at least 10 days. Eotaxin protein and mRNA levels increased in lung tissue but not in BALF after challenge. IL-5 protein and mRNA levels increased both in BALF and in lung tissue. Dexamethasone reduced airway eosinophilia, AHR, and protein and mRNA for eotaxin and IL-5. Anti-murine eotaxin and anti-IL-5 antibodies alone and in combination reduced the ovalbumin-induced airway eosinophilia significantly but failed to inhibit AHR. Both dexa-methasone and anti-IL-5/anti-eotaxin inhibited the increases in lung IL-13 levels after ovalbumin challenge to a similar extent. CONCLUSION: These findings suggest that the inhibition of AHR by the glucocorticoid dexamethasone does not appear to be explained by effects on eosinophilia, eotaxin, IL-5, or IL-13.
BACKGROUND: Glucocorticoids inhibit allergen-induced airway eosinophilia and airway hyperresponsiveness (AHR). Whether glucocorticoids mediate their effects on AHR by inhibiting eotaxin and IL-5, 2 of the principal mediators of eosinophilia, or through IL-13, an important mediator of AHR, has not been established. OBJECTIVE: We sought to investigate the effects of glucocorticoids on airway eosinophilia and the expression of IL-5, eotaxin, and IL-13 in relation to the induction of AHR in a murine model of allergic asthma. METHODS:Dexamethasone (4 mg/kg) and mAbs against eotaxin (80 micro g/kg) and IL-5 (100 micro g/kg) singly and in combination were administered to immunized mice before antigen challenge. Airway responsiveness to methacholine was measured in anesthetized and mechanically ventilated animals. Eotaxin, IL-5, and IL-13 in bronchoalveolar lavage fluid (BALF), lung homogenates, or both were measured by means of ELISA. RESULTS: A single antigen challenge induced AHR that lasted at least 10 days. Eotaxin protein and mRNA levels increased in lung tissue but not in BALF after challenge. IL-5 protein and mRNA levels increased both in BALF and in lung tissue. Dexamethasone reduced airway eosinophilia, AHR, and protein and mRNA for eotaxin and IL-5. Anti-murineeotaxin and anti-IL-5 antibodies alone and in combination reduced the ovalbumin-induced airway eosinophilia significantly but failed to inhibit AHR. Both dexa-methasone and anti-IL-5/anti-eotaxin inhibited the increases in lung IL-13 levels after ovalbumin challenge to a similar extent. CONCLUSION: These findings suggest that the inhibition of AHR by the glucocorticoid dexamethasone does not appear to be explained by effects on eosinophilia, eotaxin, IL-5, or IL-13.
Authors: Dominic R Beal; David M Stepien; Sudha Natarajan; Jiyoun Kim; Daniel G Remick Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-09-27 Impact factor: 5.464
Authors: William R Henderson; Gertrude K S Chiang; Ying-Tzang Tien; Emil Y Chi Journal: Am J Respir Crit Care Med Date: 2005-12-30 Impact factor: 21.405
Authors: Gloria S Forkuo; Margaret L Guthrie; Nina Y Yuan; Amanda N Nieman; Revathi Kodali; Rajwana Jahan; Michael R Stephen; Gene T Yocum; Marco Treven; Michael M Poe; Guanguan Li; Olivia B Yu; Benjamin D Hartzler; Nicolas M Zahn; Margot Ernst; Charles W Emala; Douglas C Stafford; James M Cook; Leggy A Arnold Journal: Mol Pharm Date: 2016-05-10 Impact factor: 4.939
Authors: Paul H Dahm; Jeremy B Richards; Harry Karmouty-Quintana; Kevin R Cromar; Sanjiv Sur; Roger E Price; Farhan Malik; Chantal Y Spencer; Ramon X Barreno; Syed S Hashmi; Michael R Blackburn; Ikram U Haque; Richard A Johnston Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-07-09 Impact factor: 3.619
Authors: Richard A Johnston; Ming Zhu; Yadira M Rivera-Sanchez; Frank L Lu; Todd A Theman; Lesley Flynt; Stephanie A Shore Journal: Am J Respir Crit Care Med Date: 2007-07-19 Impact factor: 21.405
Authors: Dong-Seon Kim; Seung-Hyung Kim; Bok-Kyu Kim; Min Cheol Yang; Jin Yeul Ma Journal: Evid Based Complement Alternat Med Date: 2011-11-15 Impact factor: 2.629